Suraksha Diagnostic Limited has informed the Exchange about Transcript
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic filed the transcript of its Q4 FY25 earnings call held on May 30, 2025. For FY25, total income grew ~15% to Rs. 2,559.4 million, with EBITDA up 16% to Rs. 850.9 million at ~34% margin and PAT up 34% to Rs. 309.8 million. The company served 1.19 million patients with 6.7 million tests across 55 centers. Management guided FY26 revenue growth of 18-20% and EBITDA margin expansion to ~36%, backed by CAPEX of ~Rs. 70 crore and plans to add 15-18 new centers. They also completed the 63% acquisition of Fetomat Wellness in April 2025 to strengthen fetal medicine and genomics capabilities, with a genomic lab set to launch shortly.
Forward guidance of 200 bps EBITDA margin expansion and 18-20% revenue growth in FY26 is positive for shareholders. Center expansion, the Fetomat acquisition, and genomic lab launch signal aggressive growth, though execution on the 15-18 new center additions and margin uplift remains key to watch.